Boston Scientific PFA Trial: 56% Success Vs 30% Drugs, 100% PFA/LAAC Success in 122 Patients
Boston Scientific's FARAPULSE PFA platform achieved 56.0% primary effectiveness at 12 months versus 30.1% with anti-arrhythmic drugs and a 5.1% major adverse event rate, with 51.7% of patients arrhythmia-free. Concomitant PFA and WATCHMAN FLX procedures yielded 100% procedural success in 122 patients and 90.6% complete LAA closure, underscoring clinical momentum.
1. AVANT GUARD Trial Outcomes
The randomized AVANT GUARD trial met all safety and effectiveness endpoints for the FARAPULSE PFA platform, delivering a 56.0% primary effectiveness rate at 12 months compared to 30.1% with anti-arrhythmic drugs and a 5.1% major adverse event rate. At one year, 51.7% of PFA patients remained free from atrial arrhythmia recurrence versus 32.2% in the drug group.
2. ELEVATE-PF Feasibility Study
In the ELEVATE-PF trial, PVI durability improved from 80.4% in the initial feasibility cohort (n=13) to 96.4% in the optimized group (n=34), with 95.6% durability at two months in patients with persistent atrial fibrillation. No instances of stroke, pulmonary vein stenosis, hemolysis or coronary spasm were reported.
3. ALIGN-AF Real-World Concomitant Procedures
Interim data from the ALIGN-AF sub-study of 122 patients across 12 sites showed 100% acute success with the FARAWAVE PFA catheter and 100% procedural success with WATCHMAN FLX, with 90.6% complete LAA closure at a mean of 66 days and no clinically relevant leaks or device-related thrombus.
4. WATCHMAN FLX Sub-Analyses and Long-Term Outcomes
A CHAMPION-AF sub-analysis found the WATCHMAN FLX device reduced major and non-major bleeding (9.0% vs. 17.0% with NOACs in ablated patients; 12.8% vs. 20.8% in non-ablated) with similar stroke prevention. Five-year ASAP-TOO follow-up showed LAAC devices cut stroke or systemic embolism rates to 7.8% versus 11.4%, with fewer disabling strokes (1.1% vs. 3.8%).